These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1099 related items for PubMed ID: 3510774

  • 1. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
    Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E.
    Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
    [Abstract] [Full Text] [Related]

  • 2. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
    Monrad ES, Baim DS, Smith HS, Lanoue AS.
    Circulation; 1986 Mar; 73(3 Pt 2):III168-74. PubMed ID: 3510773
    [Abstract] [Full Text] [Related]

  • 3. [Additive effects of milrinone and dobutamine in severe heart failure].
    Meissner A, Herrmann G, Gerdesmeyer L, Simon R.
    Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
    [Abstract] [Full Text] [Related]

  • 4. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS.
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [Abstract] [Full Text] [Related]

  • 5. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
    Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS.
    J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
    [Abstract] [Full Text] [Related]

  • 6. Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure.
    Sonnenblick EH, Grose R, Strain J, Zelcer AA, LeJemtel TH.
    Circulation; 1986 Mar; 73(3 Pt 2):III162-7. PubMed ID: 3510772
    [Abstract] [Full Text] [Related]

  • 7. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
    Travill CM, Pugh S, Noble MI.
    Clin Ther; 1994 Mar; 16(5):783-92. PubMed ID: 7859237
    [Abstract] [Full Text] [Related]

  • 8. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
    Domínguez de Rozas JM, Guindo Soldevila J, Rodríguez Font E, Martínez Vílchez R.
    Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
    [Abstract] [Full Text] [Related]

  • 9. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
    Meissner A, Schmelzle T, Simon R.
    Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
    [Abstract] [Full Text] [Related]

  • 10. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
    Pflugfelder PW, O'Neill BJ, Ogilvie RI, Beanlands DS, Tanser PH, Tihal H, Mizgala HF, Fitchett DH, Kostuk WJ.
    Can J Cardiol; 1991 Nov; 7(1):5-10. PubMed ID: 2025794
    [Abstract] [Full Text] [Related]

  • 11. Beta-adrenergic inotropic responsiveness of patients with heart failure: studies with intracoronary dobutamine infusion.
    Colucci WS, Leatherman GF, Ludmer PL, Gauthier DF.
    Circ Res; 1987 Oct; 61(4 Pt 2):I82-6. PubMed ID: 3652407
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA, Marsh KC, Polakowski JS, Fryer RM.
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparisons of the depressor, inotropic and renal effects of milrinone and CI-930 to different pure vasodilators and diuretics in conscious instrumented dogs.
    Lee KC, Clas DM, Gorczyca WP, Silver PJ, Ezrin AM.
    Drugs Exp Clin Res; 1991 Apr; 17(7):323-36. PubMed ID: 1686584
    [Abstract] [Full Text] [Related]

  • 17. [Hemodynamic study of intravenous milrinone in 26 patients with NYHA class III or IV cardiac failure].
    Boesch C, Dubois-Rande JL, Pochmalicki G, Lellouche D, Teiger E, Saal JP, Cachin JC, Mallo C, Castaigne A, Jan F.
    Ann Cardiol Angeiol (Paris); 1992 Nov; 41(9):509-12. PubMed ID: 1298193
    [Abstract] [Full Text] [Related]

  • 18. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P, Ramaprasad S.
    Pharmacotherapy; 1997 Nov; 17(2):371-4. PubMed ID: 9085331
    [Abstract] [Full Text] [Related]

  • 19. Dog model to study the effects of pharmacologic agents on the peripheral circulation: effects of milrinone.
    Lee RW, Gay RG, Lancaster LD, Olajos M, Goldman S.
    J Pharmacol Exp Ther; 1987 Mar; 240(3):1014-9. PubMed ID: 3559967
    [Abstract] [Full Text] [Related]

  • 20. Milrinone versus dobutamine: contribution of altered myocardial mechanics and augmented inotropic state to improved left ventricular performance.
    Borow KM, Neumann A, Lang RM.
    Circulation; 1986 Mar; 73(3 Pt 2):III153-61. PubMed ID: 3943179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.